Pravastatin to Prevent Preeclampsia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 102 participants.

Also called NCT03944512

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 102 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03944512
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03944512. Randomized; double masking; primary purpose prevention. Start 2019-07-17 (actual); primary completion 2021-06-06 (actual). Results posted on 2025-12-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Pravastatin to Prevent Preeclampsia
Acronym
Pravastatin
Condition
Preeclampsia
Condition
Obstetric Labor Complications
Condition
Hypertension in Pregnancy
Intervention (Drug)
Pravastatin
Intervention (Other)
Placebo
Lead sponsor
The George Washington University Biostatistics Center (class: other)
Collaborator
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (class: US National Institutes of Health)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct03944512
Content hash
28226bf3fb0805416be739ef2497a26ae483580451acb355eeda43ba159f0cec